Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Approves Reblozyl for Anemia in Adults with Lower-Risk Myelodysplastic Syndromes
April 4th 2020The Food and Drug Administration approved the first and only erythroid maturation agent to treat patients with MDS who require red blood cell transfusions and have failed an erythropoiesis stimulating agent.
Read More
Creating a Community Around Hope for Stomach Cancer
March 12th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with Aki Smith, founder of Hope for Stomach Cancer, about her journey as her father’s caregiver and what she hopes the organization offers for others affected by a stomach cancer diagnosis.
Read More
Artist Uses Talents to Illustrate Stories of Those with Myeloproliferative Neoplasms
March 10th 2020Jeffrey Glen Jones – an American illustrator who started doing comic books about 25 years ago – is using his creative talents to illustrate the stories of those impacted by MPNs, as part of a campaign called Rare Reflections: MPNs Unmasked.
Read More
MONALEESA-7 Trial Follow-Up Shows Maintained, Improved Quality of Life, Work Productivity
March 6th 2020Premenopausal women with HR-positive, HER2-negative advanced breast cancer experienced improved survival and quality of life with the addition of Kisqali to Zoladex and endocrine therapy to their treatment regimen.
Read More
Study Finds No Difference in Psychosocial Scores Following Contralateral Mastectomy
March 6th 2020Women who had contralateral prophylactic mastectomy reported similar breast satisfaction and quality of life, cancer-related distress and anxiety and depression scores, compared with those who did not undergo the procedure.
Read More
Speaking Out on Non-Small Cell Lung Cancer
February 27th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.
Read More
Novel Agent Shows Promise in Patients with Clear Cell Renal Cell Carcinoma
February 19th 2020MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.
Read More